$11.38
0.70%
Nasdaq, Aug 29, 10:00 pm CET
ISIN
US75382E1091
Symbol
RAPT

RAPT Therapeutics Inc Stock price

$11.38
-0.15 1.30% 1M
+2.26 24.78% 6M
-1.26 9.97% YTD
-5.98 34.45% 1Y
-212.70 94.92% 3Y
-201.42 94.65% 5Y
-92.62 89.06% 10Y
-92.62 89.06% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
-0.08 0.70%
ISIN
US75382E1091
Symbol
RAPT
Industry

Key metrics

Basic
Market capitalization
$188.2m
Enterprise Value
$19.3m
Net debt
positive
Cash
$169.0m
Shares outstanding
16.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.1
Financial Health
Equity Ratio
79.0%
Return on Equity
-68.5%
ROCE
-68.4%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-112.0m | $-85.6m
EBIT
$-113.1m | $-90.2m
Net Income
$-106.5m | $-56.6m
Free Cash Flow
$-92.1m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
12.4% | 36.5%
EBIT
12.5% | 33.7%
Net Income
12.2% | 56.5%
Free Cash Flow
12.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-4.0
FCF per Share
$-5.6
Short interest
3.2%
Employees
68
Rev per Employee
$0.0
Show more

Is RAPT Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

RAPT Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a RAPT Therapeutics Inc forecast:

8x Buy
67%
4x Hold
33%

Analyst Opinions

12 Analysts have issued a RAPT Therapeutics Inc forecast:

Buy
67%
Hold
33%

Financial data from RAPT Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 29 29
4% 4%
-
- Research and Development Expense 84 84
17% 17%
-
-112 -112
12% 12%
-
- Depreciation and Amortization 1.06 1.06
17% 17%
-
EBIT (Operating Income) EBIT -113 -113
12% 12%
-
Net Profit -106 -106
12% 12%
-

In millions USD.

Don't miss a Thing! We will send you all news about RAPT Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

RAPT Therapeutics Inc Stock News

Neutral
GlobeNewsWire
5 days ago
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced that members of the RAPT management team will participate in the following invest...
Neutral
GlobeNewsWire
25 days ago
SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT) (“RAPT” or the “Company”), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today reported financial results for the second quarter and six months ...
Neutral
GlobeNewsWire
2 months ago
SOUTH SAN FRANCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and immunological diseases, today announced the appointment of Scott Braunstein, M.D., and Ashley Dombkowski, Ph.D., to its b...
More RAPT Therapeutics Inc News

Company Profile

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 2 portion of a Phase 1/2 clinical trial to evaluate as a monotherapy and in combination with pembrolizumab in patients with various types of charged tumors. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into allergically-inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

Head office United States
CEO Brian Wong
Employees 68
Founded 2015
Website rapt.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today